(Alliance News) - Allergy Therapeutics PLC on Monday said it appointed Martin Hopcroft as interim chief financial officer, as Nick Wykeman will step down at the end of November.

Allergy Therapeutics is a West Sussex-based commercial biotechnology company.

Hopcroft was previously CFO at Novasep SA, a supplier of pharmaceuticals and biopharmaceuticals. During his tenure, Novasep won a contract with AstraZeneca to support the production of the active substance of its adenovirus vector-based Covid-19 vaccine.

Hopcroft also served as CFO at formerly listed Cambian Group PLC, a provider of specialist residential and educational services for children and young adults, and at Consort Medical PLC, a medical devices company.

In the role, Hopcroft will report to Chief Executive Manuel Llobet, once Wykeman steps down this month to pursue non-executive roles.

Allergy Therapeutics said it is searching for a permanent CFO.

Allergy Therapeutics shares were down 3.3% to 14.50 pence on Monday afternoon in London.

By Jaskeet Briah; jaskeetbriah@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.